Synergistic effect of sorafenib with Platycladus orientalis (L) leaf extract on cervical cancer

Elvis Samuel; D. David Wilson; Catherene Tomy; D. Jerome Inder Nallakannu; Siddikuzzaman; Aavany Balasubramanian; V. M. Berlin Grace

doi:10.14393/BJ-v39n0a2023-62558

Authors

Elvis Samuel Karunya Institute of Technology and Sciences https://orcid.org/0000-0002-0265-4169
D. David Wilson Karunya Institute of Technology and Sciences https://orcid.org/0000-0003-2356-0011
Catherene Tomy Karunya Institute of Technology and Sciences https://orcid.org/0000-0002-9148-237X
D. Jerome Inder Nallakannu Karunya Institute of Technology and Sciences https://orcid.org/0000-0002-5960-2378
Siddikuzzaman Galaxy Health Care https://orcid.org/0000-0002-9369-6750
Aavany Balasubramanian Karunya Institute of Technology and Sciences
V. M. Berlin Grace Karunya Institute of Technology and Sciences https://orcid.org/0000-0002-8459-0946

DOI:

https://doi.org/10.14393/BJ-v39n0a2023-62558

Keywords:

Bcl-2, Franco, HeLa cells, PCNA, Platycladus orientalis (L.), Sorafenib, TIG3.

Abstract

The extracts of Platycladus orientalis (L.) Franco leaves have shown promising anti-cancer, anti-oxidant and anti-inflammatory potency with the traditional knowledge of healing HPV associated warts. The purpose of this research is to assess the synergistic activity of sorafenib and Platycladus orientalis (L) leaf extraction on cervical cancer cells. The cytotoxicity efficiency of different concentrations of Sorafenib and ethanol extract of Platycladus orientalis (L.) leaves were tested on HeLa cells by MTT and Trypan blue assays. The synergistic effect of the IC₅₀ concentrations of Sorafenib and Platycladus orientalis (L.) on HeLa cell by MTT assay, and mRNA expression levels of tumor suppressor tazarotene-induced gene 3 (TIG3), proliferating cell nuclear antigen (PCNA) gene and apoptosis modulator (Bcl-2) gene by RT-PCR were evaluated with individual treatments. Combination treatment showed a relatively more expression of TIG3 and less expression of Bcl-2 and PCNA was observed. Growth factor-induced MAPKP activation was arrested by compound combination treatment, which and suppression of proliferation-induced apoptosis of cervical cancer cells. Based on the our results, the combination of sorafenib and crude leaf extract from Platycladus orientalis (L.) can effectively suppress cervical cancer cell growth, thereby providing an interesting rationale for further clinical trials and in-vivo studies.

Downloads

Download data is not yet available.

References

AMIRGHOFRAN, Z. and KARIMI, M.H. Cytotoxic Activity Of Thymus Vulgaris, Achillea Millefolium And Thuja Orientalis On Different Growing Cell Lines. Medical Journal of The Islamic Republic of Iran. 2001, 15(3),149-154. http://mjiri.iums.ac.ir/article-1-797-en.html

BASYAL, S., et al. 1096: Alcohol intoxication in a secured hospital unit. Critical Care Med. 2018, 46(1),531-531. https://doi.org/10.1097/01.ccm.0000529101.81482.bf

BEERAM, M., PATNAIK, A. and ROWINSKY, E.K. Raf: A Strategic Target for Therapeutic Development Against Cancer. Journal Clinical Oncology. 2005, 23(27),6771-6790. https://doi.org/10.1200/JCO.2005.08.036

BERMUDEZ, A., BHATLA, N. and LEUNG, E. Cancer of the cervix uteri. International Journal of Gynecology & Obstetrics. 2015, 131,S88-S95. https://doi.org/10.1016/j.ijgo.2015.06.004

BIERBRAUER, A., et al. A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. British Journal of Cancer. 2020,122(10),1544-1551. https://doi.org/10.1038/s41416-020-0795-9

BRANCA, M., et al. Up-regulation of proliferating cell nuclear antigen (PCNA) is closely associated with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2007, 130(2),223-231. https://doi.org/10.1016/j.ejogrb.2006.10.007

BRAY, F., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer Journal for Clinicians. 2018, 68(6),394-424. https://doi.org/10.3322/caac.21492

CARDANO, M., TRIBIOLI, C. and PROSPERI, E. Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation. Current Cancer Drug Targets. 2020, 20(4),240-252. https://doi.org/10.2174/1568009620666200115162814

CHANG, F., et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). International Journal of Oncology. 2003, 22(3),469-480.

CHATTERJEE, K., et al. Dietary Polyphenols, Resveratrol and Pterostilbene Exhibit Antitumor Activity on an HPV E6-Positive Cervical Cancer Model: An in vitro and in vivo Analysis. Frontiers in Oncology. 2019, 9, 352. https://doi.org/10.3389/fonc.2019.00352

CHEN, P.N., et al. Mulberry anthocyanins, cyanidin 3-rutinoside and cyanidin 3-glucoside, exhibited an inhibitory effect on the migration and invasion of a human lung cancer cell line. Cancer Letters. 2006, 235(2),248-259. https://doi.org/10.1016/j.canlet.2005.04.033

COURTNEY, K.D., CORCORAN, R.B. and ENGELMAN, J.A. The PI3K Pathway As Drug Target in Human Cancer. Journal of Clinical Oncology. 2010, 28(6),1075-1083. https://doi.org/10.1200/JCO.2009.25.3641

ENGLISH, J.M. and COBB, M.H. Pharmacological inhibitors of MAPK pathways. Trends in Pharmacological Sciences. 2002, 23(1),40-45. https://doi.org/10.1016/s0165-6147(00)01865-4

FINUCANE, D.M., et al. Bax-induced Caspase Activation and Apoptosis via Cytochromec Release from Mitochondria Is Inhibitable by Bcl-xL. Journal of Biological Chemistry. 1999, 274(4),2225-2233. https://doi.org/10.1074/jbc.274.4.2225

FLETCHER, J.I., et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proceedings of the National Academy of Sciences of the United States of America. 2008, 105(47),18081-18087. https://doi.org/10.1073/pnas.0808691105

GAN, D.L., et al. Volatile Oil of Platycladus Orientalis (L.) Franco Leaves Exerts Strong Anti-inflammatory Effects via Inhibiting the IκB/NF-κB Pathway. Current Medical Science. 2021, 41(1),180-186. https://doi.org/10.1007/s11596-020-2301-2

GHAEMMAGHAMI, F., et al. Risk Factors and Clinical Aspects of Recurrent Invasive Cervical Carcinoma. Journal of Obstetrics and Gynecology of India. 2012, 62(6),674-678. https://doi.org/10.1007/s13224-012-0227-8

GULERIA, S., KUMAR, A. and TIKU, A.K. Chemical Composition and Fungitoxic Activity of Essential Oil of Thuja orientalis L. Grown in the North-Western Himalaya. Zeitschrift für Naturforsch C. 2008, 63(3-4),211-214. https://doi.org/10.1515/znc-2008-3-409

HOWLADER, N., et al. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/

HUANG, S.L., et al. The retinoid-inducible gene I: effect on apoptosis and mitogen-activated kinase signal pathways. Anticancer Research. 2002, 22(2A),799-804.

HUANG, S.X., et al. A Designer Bleomycin with Significantly Improved DNA Cleavage Activity. Journal of the American Chemical Society. 2012, 134(32),13501-13509. https://doi.org/10.1021/ja3056535

HUETHER, A., et al. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World Journal of Gastroenterology. 2006, 12(32),5160-5167. https://doi.org/10.3748/wjg.v12.i32.5160

HUETHER, A., et al. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochemical Pharmacology. 2007, 73(9), 1308-1317. https://doi.org/10.1016/j.bcp.2006.12.031

HUSSAIN, S.P., HOFSETH, L.J. and HARRIS, C.C. Radical causes of cancer. Nature Reviews Cancer. 2003, 3(4),276-285. https://doi.org/10.1038/nrc1046

JIANG, B. and LIU, L. Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis. In:19-65. 2009. https://doi.org/10.1016/S0065-230X(09)02002-8

KEATING, G.M. and SANTORO, A. Sorafenib. Drugs. 2009, 69(2),223-240. https://doi.org/10.2165/00003495-200969020-00006

KIM, T.H., et al. A new labdane diterpenoid with anti-inflammatory activity from Thuja orientalis. Journal of Ethnopharmacology. 2013, 146(3),760-767. https://doi.org/10.1016/j.jep.2013.02.001

KOHNO, M. and POUYSSEGUR, J. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs. Progress in Cell Cycle Research. 2003, 5,219-24.

KOLCH, W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochemical Journal. 2000, 351,289–305.

KOLENDA, T., et al. Quantification of long non-coding RNAs using qRT-PCR: comparison of different cDNA synthesis methods and RNA stability. Archives of Medical Science. 2021, 17(4), 1006–1015. https://doi.org/10.5114/aoms.2019.82639

LIN, M.T., et al. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. Tumor Biology. 2016, 37(5),6987-6996. https://doi.org/10.1007/s13277-015-4526-4

LIU, L., et al. Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5. Cancer Research. 2006, 66(24),11851-11858. https://doi.org/10.1158/0008-5472.CAN-06-1377

LLOVET, J. M., et al. Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine. 2008, 359(4),378-390. https://doi.org/10.1056/NEJMoa0708857

LOIZZO, M. R., et al. Phytochemical analysis and in vitro antiviral activities of the essential oils of seven Lebanon species. Chemistry and Biodiversity. 2008, 5(3),461-470. https://doi.org/10.1002/cbdv.200890045

LOTZ, K., et al. Suppression of theTIG3 tumor suppressor gene in human ovarian carcinomas is mediatedvia mitogen-activated kinase-dependent and -independent mechanisms. International Journal of Cancer. 2005, 116(6),894-902. https://doi.org/10.1002/ijc.21127

MANCI, N., et al. A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecologic Oncology. 2011,122(2),285-290. https://doi.org/10.1016/j.ygyno.2011.04.013

MARCHETTI, A., et al. EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment. J Clin Oncol. 2005, 23(4),857-865. https://doi.org/10.1200/JCO.2005.08.043

OUYANG, Y., et al. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing oxazole or imidazole as potential EGFR inhibitors. New Journal of Chemistry. 2018, 42(21),17203-17215. https://doi.org/10.1039/C8NJ03594F

PIROUZFAR, M., et al. CRISPR/Cas9-mediated knockout of MLL5 enhances apoptotic effect of cisplatin in HeLa cells in vitro. EXCLI Journal. 2020, 19,170-182. https://doi.org/10.17179/excli2019-1957

PUCH-HAU, C., et al. Evaluation of two independent protocols for the extraction of DNA and RNA from different tissues of sea cucumber Isostichopus badionotus. MethodsX. 2019, 6,1627-1634. https://doi.org/10.1016/j.mex.2019.07.010

RAMALHO, A.S., et al. Methods for RNA extraction, cDNA preparation and analysis of CFTR transcripts. Journal of Cystic Fibrosis. 2004, 3,11-15. https://doi.org/10.1016/j.jcf.2004.05.004

REN, Y., et al. EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma. OncoTargets and Therapy. 2015, 8, 3017-20. https://doi.org/10.2147/OTT.S87146

RODEN, R. and WU, T.C. How will HPV vaccines affect cervical cancer? Nature Reviews Cancer. 2006, 6(10),753-763. https://doi.org/10.1038/nrc1973

RUBINFELD, H. and SEGER, R. The ERK Cascade: A Prototype of MAPK Signaling. Molecular Biotechnology. 2005, 31(2),151-174. https://doi.org/10.1385/MB:31:2:151

SANFELICE, R.A., et al. Pravastatin and simvastatin inhibit the adhesion, replication and proliferation of Toxoplasma gondii (RH strain) in HeLa cells. Acta Tropica. 2017, 167,208-215. https://doi.org/10.1016/j.actatropica.2016.12.006

SCHARADIN, T.M. and ECKERT, R.L. TIG3: An Important Regulator of Keratinocyte Proliferation and Survival. Journal of Investigative Dermatology. 2014, 134(7),1811-1816. https://doi.org/10.1038/jid.2014.79

SINGH, A. and SINGH, V.K. Molluscicidal activity of Saraca asoca and Thuja orientalis against the fresh water snail Lymnaea acuminata. Veterinary Parasitology. 2009, 164(24),206-210. https://doi.org/10.1016/j.vetpar.2009.05.008

SMALLEY, K. S., et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 2009,28(1),85-94. https://doi.org/10.1038/onc.2008.362

SRISAIKHAM, S. A Comparison of Nutritional Values, Bioactive Compounds, Amino Acids, and Antioxidant Activities of Alfalfa (Medicago sativa) Plant and Pellet for Use as Beneficial Material Ruminant Feed. Walailak Journal of Science and Technology. 2021,18(5). Article 10312 (16 pages). https://doi.org/10.48048/wjst.2021.10312

SRIVASTAVA, P., et al. Biological Properties of Thuja Orientalis Linn. Advances in life sciences. 2012, 2(2),17-20. https://doi.org/10.5923/J.ALS.20120202.04

TEWARI, K.S., et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017, 390(10103),1654-1663. https://doi.org/10.1016/S0140-6736(17)31607-0

TISEO, M., et al. Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). Drug Design, Development and Therapy. 2010, 4,81-98. https://doi.org/10.2147/dddt.s6594

TSAI, F.M., SHYU, R.Y. and JIANG, S.Y. RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Cellular Signalling. 2006, 18(3),349-358. https://doi.org/10.1016/j.cellsig.2005.05.005

TU, Y., et al. Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors. Computational and Structural Biotechnology Journal. 2018, 16,462-478. https://doi.org/10.1016/j.csbj.2018.10.016

UREN, R.T., et al. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. Journal of Cell Biology. 2007, 177(2),277-287. https://doi.org/10.1083/jcb.200606065

VAUX, D.L., CORY, S. and ADAMS, J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988, 335(6189),440-442. https://doi.org/10.1038/335440a0

VIVANCO, I. and SAWYERS, C.L. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nature Reviews Cancer. 2002, 2(7),489-501. https://doi.org/10.1038/nrc839

WILHELM, S.M., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics. 2008, 7(10),3129-3140. https://doi.org/10.1158/1535-7163.MCT-08-0013

WILHELM, S.M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research. 2004,64(19),7099-109. https://doi.org/10.1158/0008-5472.CAN-04-1443

ZHANG, N., PARK, D.K. and PARK, H.J. Hair growth-promoting activity of hot water extract of Thuja orientalis. BMC Complementary Medicine and Therapies. 2013, 13,9. https://doi.org/10.1186/1472-6882-13-9

ZHANG, Y., et al. Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways. Molecular Medicine Reports. 2014, 9(1),83-90. https://doi.org/10.3892/mmr.2013.1781